C. Bradley

发表

Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).

D. Patt, J. O’Shaughnessy, J. Pippen, 2009 .

Abstract P6-15-01: A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC)

S. Moulder, M. Mita, L. Harris, 2010 .

Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor.

J. O’Shaughnessy, J. Blum, C. Osborne, 2009 .

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

S. Kopetz, R. Wolff, F. Cabanillas, 2011, Anticancer research.

Abstract #5552: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer

I. Roninson, C. Lim, Lingyun Li, 2009 .

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Mark Yoffe, Debra Patt, D. Patt, 2011, The New England journal of medicine.

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.

D. Patt, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer

M. Birrer, U. Matulonis, P. Konstantinopoulos, 2023, The oncologist.

G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial

D. Patt, J. O’Shaughnessy, J. Pippen, 2009 .

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.

D. Patt, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P3-14-08: A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer.

B. Daniel, Kirstin C. Jensen, R. Carlson, 2011 .

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

D. Patt, J. O’Shaughnessy, J. Pippen, 2011, The New England journal of medicine.